Navigation Links
Anesiva Receives NASDAQ Delisting Staff Determination Letter
Date:7/23/2009

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) received, as previously disclosed on its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2009 and in its press release on April 1, 2009, a letter from the NASDAQ Stock Market LLC ("NASDAQ") on March 27, 2009, informing Anesiva that it was not in compliance with Marketplace Rule 4450(a)(3) (which has since been superseded by Rule 5450(b)(1)(A)) (the "Rule"), because Anesiva's stockholder's equity at December 31, 2008 was less than the minimum $10.0 million required for continued listing on The NASDAQ Global Market.

On July 17, 2009, Anesiva received a letter from NASDAQ notifying Anesiva that based on NASDAQ's further review of Anesiva and material submitted by Anesiva, Anesiva has failed to regain compliance with the Rule and that, therefore, NASDAQ has determined to delist the Company's securities from The NASDAQ Global Market.

Anesiva has requested a hearing before a NASDAQ Hearings Panel to appeal the determination to delist Anesiva's securities. Anesiva's securities will remain listed on The NASDAQ Global Market pending a decision by the Hearings Panel following the hearing.

About Anesiva

Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. The company's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

In Dece
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
2. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
3. Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
4. Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
7. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
8. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
9. Anesiva Announces First Quarter 2008 Financial Results
10. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
11. Anesiva Announces Expansion of Zingo Agreement in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015  Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal and metabolic diseases, today announced that ... Company,s Board of Directors. Dr. Jenkins brings a ... having built and led teams advancing programs from ... into healthcare systems globally. "Annalisa ...
(Date:4/20/2015)... 2015 /CNW/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, Portage ... that showed one of its proprietary human-derived CPP sequences ... through inhibition of NFkB signalling even if administered when ... of the blood brain barrier (BBB) in mice was ...
(Date:4/18/2015)... 2015 Aurigene and its ... be presenting data at the poster sessions from ... Research Annual Meeting (April 18-22 in ... http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene will ... small molecule inhibitors program, which is currently in ...
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the ... today announced the hiring of William Tanner ... Mr. Tanner will start work at Guggenheim ... York office. "Bill brings a ... research, to our experienced and highly acclaimed healthcare team," ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2
... 7, 2008 MaxCyte, Inc., a,clinical-stage therapeutics ... loading systems, announces that Anthony Recupero, Ph.D.,Vice ... on Tuesday,April 8, 2008, at 2:00PM at ... Dr. Recupero,s presentation will discuss the development ...
... Excellence and Patient Ease-of-Use, BROOKFIELD, Wis., April ... won the 2008 Medical Design Excellence Awards (MDEA) ... Genesis DM won in the,rehabilitation and assistive-technology products ... monitoring device is,ideal for both the patient and ...
... Boston,Scientific Corporation (NYSE: BSX ) will webcast ... ended March 31, 2008 on,Tuesday, April 22, at 8:30 ... Jim Tobin, President and Chief Executive,Officer, Paul LaViolette, Chief ... Financial Officer., The live webcast and archived replay ...
Cached Biology Technology:Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3Boston Scientific to Webcast Conference Call Discussing First Quarter Financial Results 2
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... In 2005, 40.3 million people in the world, including 25.8 ... of the origin of HIV-1, responsible for the AIDS pandemic, ... Some months ago, the team of Martine Peeters, director of ... research unit UMR 145 jointly involving the IRD and the ...
... among other roles. For the first time, scientists using ... of its kind in the Americas) have seen how ... the first aid/repair after DNA injuries to the region ... lie out of the visual reach of scientists. The benefits ...
... University researchers have shown that some simple biodegradable liquids ... development that could significantly impact medicine. , When the ... to open wounds, the peptides self-assemble into a nanoscale ... bleeding. Once the injury heals, the nontoxic gel is ...
Cached Biology News:Wild gorillas carriers of a SIV virus close to the AIDS virus 2Nanoscale microscope sheds first light on gene repair 2MIT material stops bleeding in seconds 2MIT material stops bleeding in seconds 3
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Stabilizer is an aqueous solution that contains ... stabilizing chemicals in a saline solution, pH ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ... a diluent and stabilizer for biologically active ...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
Biology Products: